Victoria Savage is Chief Scientific Officer at INFEX Therapeutics Ltd, an infection-focussed biotechnology company based in Cheshire in the United Kingdom. Victoria is a microbiologist with a keen interest in antimicrobial drug discovery and development and has contributed to the development of numerous antimicrobial programmes, from early-stage development of hit molecules through to clinical-stage projects. She has experience in the development of diverse modalities including small molecules, biologics, and non-traditional approaches.
Victoria also holds several advisory roles in the biological sciences and AMR space. She is a member of the UK’s Biotechnology and Biological Sciences Research Council (BBSRC) Pool of Experts, she sits on the Industrial Advisory Board for Newcastle University’s Faculty of Medical Sciences (UK) and is also a member of the UK’s Cystic Fibrosis AMR Syndicate Steering Committee. She earned both her BSc in Microbiology and Immunology, and PhD in Microbiology, from the University of Leeds in the UK.